Background Cisplatin-induced kidney injury remains a major obstacle in utilizing cisplatin as
a chemotherapeutic for solid-organ cancers. Thirty percent of patients treated with cisplatin
develop acute kidney injury (AKI), and even patients who do not develop AKI are at risk for
long-term declines in kidney function and development of chronic kidney disease (CKD).
Modeling cisplatin-induced kidney injury in mice has revealed that repeated low doses of
cisplatin lead to development of kidney fibrosis. This model can be used to examine AKI-to …